Sam Zhang, PhD
Vice President, Head of Microbial and Viral Platforms (MVP)
WuXi Biologics
- Time:
In biomanufacturing, there are complex demands around fermentation scale-up, process consistency, technology transfer, and manufacturing capacity that must be addressed for microbial-derived biologics to complete commercialization. Meeting those demands depends on specialized infrastructure and an integrated strategy for process validation, process performance qualification (PPQ), and long-term operational readiness.
In this GEN webinar, our expert speaker, Sam Zhang, PhD, will discuss emerging trends and capacity needs across the global late-stage microbial pipeline and CDMO landscape. He will introduce WuXi Biologics’ integrated late-stage microbial capabilities including the newly constructed commercial facility in Chengdu, China, designed for microbial-derived biologics. He will demonstrate features of the comprehensive tech transfer and scale-up platform, as well as PPQ and commercial readiness strategies. He will also share a case study featuring a peptide program that will elucidate WuXi Biologics’ tailored solutions for microbial-derived biologics. Key takeaways will include:
- Critical success factors for technology transfer, process scale-up, PPQ readiness and commercial manufacturing
- Large-scale microbial manufacturing capabilities at the Chengdu site, with fermentation scales of up to 15,000 L
- Practical learnings from a complex peptide program, with broader relevance to recombinant proteins and other microbial-derived modalities
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
